The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

Alberto Espay was not prepared for how his world would be upended when he published a study on the number of people who have ...

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Cogent Biosciences has cleared another phase 3 hurdle for lead asset bezuclastinib, teeing up an approval submission for a form of gastrointestinal cancer in the first half of next year.

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

Drug & Device Team provides recommendations based on Food & Drug Administration (FDA) draft guidance on Quality Management System ...

CRRT (Continuous Renal Replacement Therapy): A form of dialysis used for critically ill patients that continuously removes ...

Discover key Q3 2025 insights from Achieve Life Sciences as they expedite cytisinicline’s FDA approval for nicotine dependence.

As drug development enters a new era, Certara is expanding its global team of scientists and technologists to lead the shift toward AI-powered testing methods.